IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET® platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas IPH6501 is progressing towards a Phase 1 clinical trial in 2023 MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Innate Pharma SA...

Carbios has recently consolidated key partnerships with Indorama Ventures and Novozymes, and has announced funding and investment of over €150 million for the first PET biorecycling plant in the world the cost of which has been re-estimated at €230...

LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS CANbridge to Hold Investor CallBEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development...

Faraday Future has debuted the first All-Ability aiHypercar, the FF 91 2.0 Futurist Alliance, which has undergone a comprehensive upgrade and iteration in its technological architecture since the FF 91 introduction six years ago. Faraday Future announced the AI-Powered “6x4...

Production guidance from Hess Corporation for the Stabroek Block indicates a reduction in 2023 Q2 compared to the prior quarter, as Exxon moves to execute maintenance on the Liza Phase 2 project.  Net production for Hess, a 30% stakeholder in...

SAR’579/IPH6101, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was well tolerated and induced 3...

The latest crash-test achievement joins the announcements made late last year of the FF91’s EPA rating of 381 miles of EV range and the official CARB certification received as a zero-emissions vehicle. The first phase of the Company’s three-phase delivery...

Treatment of all Phase Ia cohorts in monotherapy completed with no safety concerns Stabilization of injected lesions in 11/18 patients An independent Safety Review Committee has approved initiation of the combination trial with pembrolizumabSTRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Euronext...

After a Single Administration of JK07, Patients in All Dose Cohorts Showed Improvement in Ejection Fraction (EF) Through Day 90 JK07 was Generally Safe and Well-Tolerated JK07 is a First-in-class Antibody Fusion and Selective ErbB4 Agonist Company Plans to Initiate Phase 2...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting...